Skip to content

Psilocybin and microdosing

Studies whose primary subject is both Psilocybin and Microdosing, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, Microdosing, micro-dosing, then ranked by relevance.

Across the research, self-reported benefits of psilocybin microdosing (improved mood, mental health, creativity, focus) are widely reported by users, but placebo-controlled trials consistently fail to confirm these effects: the largest RCT in major depressive disorder found no advantage over placebo, and controlled lab studies found no benefit for mood, cognition, or creativity. The most consistent signals are expectancy effects, a small possible decrease in cognitive control, and unresolved long-term safety questions such as valvular heart disease risk. Evidence quality is generally low, with small samples, high risk of bias, and few rigorous trials.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Motives and Side-Effects of Microdosing With Psychedelics Among Users 2019 cross-sectional survey 1116 Mixed Performance enhancement was the main motive for microdosing, but the most common reason for stopping was lack of effectiveness, and negative effects were mostly acute psychological effects.
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study 2022 double-blind placebo-controlled experimental study 34 No effect 0.5 g of dried psilocybin mushrooms produced noticeable subjective effects and altered EEG rhythms but did not enhance well-being, creativity, or cognitive function, with a few small changes toward cognitive impairment.
Psychedelic microdosing benefits and challenges: an empirical codebook 2019 mixed-methods study Unclear Argues that a taxonomy of participant-reported microdosing benefits and challenges can frame and prioritize future scientific research.
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. 2019 observational cohort 1000 Supports Spaced repeated microdoses of LSD (10 micrograms every three days) were followed by improvements in negative moods, especially depression, and increases in positive moods, along with increased energy and work effectiveness.
Microdosing psychedelics: Motivations, subjective effects and harm reduction 2019 cross-sectional survey 525 Supports Microdosing was primarily used as self-managed therapy for mental health, with perceived short-term benefits including improved mood and anxiety, enhanced connection, and cognitive enhancement, and most reported at least one harm reduction practice.
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities 2020 cross-sectional survey 909 Mixed Microdosers were significantly less likely to report a history of substance use disorders or anxiety disorders but more likely to report recent recreational substance use compared with non-microdosers.
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study 2021 randomized controlled trial No effect Psilocybin microdosing did not affect emotion processing or symptoms of anxiety and depression compared with placebo, and did not affect self-reported interoceptive awareness.
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review 2020 systematic review Mixed Highly contradictory results were found, showing both benefits and detriments of microdosing in terms of mood, creative processes, and energy, with notable limitations such as gender bias and heterogeneity of dosing.
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention 2020 cross-sectional survey 6753 Mixed Perceived benefits of microdosing greatly outweighed challenges, but approach-intention predicted fewer benefits, and most participants did not test their substances.
Microdosing psilocybin for chronic pain: a case series 2022 case series 3 Supports Low-dose psilocybin self-administered by three patients provided robust pain relief without psychedelic effects and reduced reliance on traditional analgesics.
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls 2022 naturalistic observational study 1133 Supports Psilocybin microdosing was associated with small to medium improvements in mood and mental health, and among older adults combining psilocybin with lion's mane and niacin was linked to psychomotor improvements.
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study 2021 preregistered combined field- and lab-based crossover study Mixed Participants felt more awe in response to videos when microdosing psilocybin compared to placebo, but about two-thirds broke blind, suggesting expectancy effects may drive subjective benefits.
Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats 2018 experimental study 40 Opposes Microdosing with ketamine or psilocin produced a mildly anxiogenic profile in rats, suggesting microdosing for therapeutic purposes might be counter-productive.
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. 2023 experimental study Supports Repeated low doses of psilocybin in rats imparted stress resilience, reduced compulsive-like grooming, and increased 5-HT7 receptor expression and synaptic density in the paraventricular nucleus of the thalamus.
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease 2023 review Opposes Chronic psychedelic microdosing may pose a risk of valvular heart disease due to 5-HT2B receptor activation, but appropriate studies are lacking.
Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis 2026 theoretical paper Unclear Proposes that daily low-dose psilocybin may induce progressive 5-HT2A receptor desensitization, with fading subjective effects marking an adaptive state rather than therapeutic failure, and that intermittent schedules may test different chronic pharmacology.
The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing 2026 systematic review 3262 Mixed Some studies suggest microdosing may improve well-being, mental health, cognition, and other outcomes, but evidence is low certainty and causal effects cannot be inferred; motivations were mostly non-medical and adverse events rarely reported.
Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 preclinical experimental study No effect Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, or novelty seeking, and did not increase dentate gyrus cell proliferation, though a small anxiogenic effect was observed.
Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis 2026 umbrella review 1614 Opposes The only significant pooled effect was a small decrease in cognitive control; mood benefits were not replicated under placebo-controlled conditions.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM. 2026 corrigendum Unclear This is a corrigendum to a study protocol for microdosing psilocybin for MDD; no results are reported.
Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT 2026 observational study Mixed Psilocybin microdosing was associated with subtle EEG effects including reduced global field power and frequency-specific delta- and theta-band microstate alterations, with no significant broadband changes.
Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults 2026 cross-sectional survey 1523 Mixed Cannabis was the most commonly microdosed substance (9.4% lifetime prevalence), followed by psilocybin (5.3%) and LSD (4.8%); psilocybin, LSD, and MDMA were more commonly microdosed for recreational purposes, and microdosing was more common among those with poorer mental health.
Psilocybin microdosing in the United States: Insights from a nationally representative survey 2026 survey study Supports At least 8.4 million US adults have microdosed psilocybin, with improving physical and mental health as the top motivations.
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial 2026 randomized controlled trial 39 No effect Repeated low doses of psilocybin (2 mg) did not demonstrate statistically greater efficacy than placebo for reducing depressive symptoms over four weeks.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial 2026 phase II randomized controlled trial protocol 40 Unclear This is a study protocol; the primary outcome of change in depression symptoms after four weeks of microdosing psilocybin versus placebo has not yet been reported.

Points of agreement

  • Self-reported benefits of microdosing (improved mood, mental health, creativity, focus) are widely reported in surveys and observational studies.
  • Placebo-controlled trials and reviews consistently fail to confirm benefits for mood, cognition, or creativity.
  • Expectancy and breaking blind are major confounders in subjective benefit reports.
  • Long-term safety of chronic microdosing, including valvular heart disease risk, is unresolved.
  • Evidence quality is generally low, with small samples, high risk of bias, and heterogeneous dosing.

Conflicts

  • Observational and survey studies report positive mood and mental health benefits, while randomized controlled trials and umbrella reviews find no significant benefit over placebo.
  • Animal studies disagree: some show stress resilience and reduced compulsive behavior, while others show anxiogenic effects or no behavioral change.
  • Some studies report cognitive enhancement, while an umbrella review found a small decrease in cognitive control.

Gaps

  • Durability of any effects beyond short-term observation is largely unstudied.
  • Blinding is frequently broken in microdosing trials, undermining placebo control.
  • Long-term safety data, especially for valvular heart disease, are lacking.
  • Optimal dosing schedules and dose ranges are not established.
  • Populations studied are narrow (mostly White, male, Western, self-selected users).
  • Few large, rigorous RCTs exist, and several are still ongoing or unpublished.
Browse these studies in the library

Common questions

What does the research agree on about psilocybin and microdosing?
  • Self-reported benefits of microdosing (improved mood, mental health, creativity, focus) are widely reported in surveys and observational studies.
  • Placebo-controlled trials and reviews consistently fail to confirm benefits for mood, cognition, or creativity.
  • Expectancy and breaking blind are major confounders in subjective benefit reports.
  • Long-term safety of chronic microdosing, including valvular heart disease risk, is unresolved.
  • Evidence quality is generally low, with small samples, high risk of bias, and heterogeneous dosing.
Where do studies on psilocybin and microdosing conflict?
  • Observational and survey studies report positive mood and mental health benefits, while randomized controlled trials and umbrella reviews find no significant benefit over placebo.
  • Animal studies disagree: some show stress resilience and reduced compulsive behavior, while others show anxiogenic effects or no behavioral change.
  • Some studies report cognitive enhancement, while an umbrella review found a small decrease in cognitive control.
What is still unknown about psilocybin and microdosing?
  • Durability of any effects beyond short-term observation is largely unstudied.
  • Blinding is frequently broken in microdosing trials, undermining placebo control.
  • Long-term safety data, especially for valvular heart disease, are lacking.
  • Optimal dosing schedules and dose ranges are not established.
  • Populations studied are narrow (mostly White, male, Western, self-selected users).
  • Few large, rigorous RCTs exist, and several are still ongoing or unpublished.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psilocybin and microdosing, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psilocybin and microdosing or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

56 articles · 25 from the last two years · 25,455 participants across 27 studies reporting sample size

Common study designs

review 6 experimental study 4 observational cohort 4 cross-sectional survey 6 randomized controlled trial 5

Research volume by year

Compare topics →

56 studies whose primary subject is psilocybin and microdosing since 2018

Studies about psilocybin and microdosing per year, 2018 to 2026, peaking at 13 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 10 20 2020 2025
2026 is partial
Show the numbers
Studies about psilocybin and microdosing per year, 2018 to 2026, peaking at 13 in 2026
Year Studies
2018 1
2019 5
2020 5
2021 5
2022 9
2023 3
2024 5
2025 10
2026 13

Research

Synthesize the evidence →

Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis

Zenodo (CERN European Organization for Nuclear Research) September 2, 2026 Andrea Vittorini

This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather...

DOI: 10.5281/zenodo.22239349 (opens in new tab)

The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing

Frontiers in Psychiatry August 19, 2026 Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.

IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...

DOI: 10.3389/fpsyt.2026.1866881 (opens in new tab) Full text (opens in new tab) Magic mushrooms Microdosing Psilocybin Psychedelic substances +1

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

DOI: 10.1016/j.pbb.2026.174231 (opens in new tab) Full text (opens in new tab) Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis

Journal of Psychopharmacology June 28, 2026 Yiğit Özaydın, Buket Canlan Özaydın

Background: Psychedelic microdosing—repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin—has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias. Methods: We conducted an umbrella review with narrative synthesis following Joanna Briggs Institute...

DOI: 10.1177/02698811261456196 (opens in new tab) Psilocybin Mood Cognition Expectancy theory +6

Characterizing Resting-State Brain Dynamics with Frequency-Resolved EEG Microstates: Parallel Analyses of Psilocybin Microdosing and Acute Inhaled DMT

bioRxiv Preprint Server May 5, 2026 Povilas Tarailis, Inga Griškova-bulanova preprint

Electroencephalographic (EEG) microstates provide a compact framework for characterizing the temporal organization of large-scale brain activity, yet their sensitivity to altered brain states remains insufficiently explored. In this study, we applied broadband and frequency-resolved EEG microstate analysis to resting-state EEG data from two publicly available datasets acquired under markedly...

DOI: 10.64898/2026.05.05.723034 (opens in new tab) Full text (opens in new tab)

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults

American Journal of Preventive Medicine May 4, 2026 Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al. 1 citation

IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...

DOI: 10.1016/j.amepre.2026.108381 (opens in new tab) Full text (opens in new tab) MDMA Medline Young adult Drug +2

Psilocybin microdosing in the United States: Insights from a nationally representative survey

Addiction March 8, 2026 Michelle Priest, Beau Kilmer, Rajeev Ramchand et al. 1 citation

At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to report microdosing the last time they used than those who have used psilocybin more than one year ago; however, approximately 15% respondents who used psilocybin in their lifetime were unsure whether they microdosed the last time they used....

DOI: 10.1111/add.70368 (opens in new tab) Psilocybin Multinomial logistic regression Epidemiology Microdose +6

Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial

Research Square February 23, 2026 Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al. preprint

Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...

DOI: 10.21203/rs.3.rs-8319478/v1 (opens in new tab) Full text (opens in new tab) Psilocybin Major depressive disorder Placebo Adverse effect +9

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial

BJPsych Open February 16, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. 1 citation

BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...

DOI: 10.1192/bjo.2025.10968 (opens in new tab) Full text (opens in new tab)

Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence

Exploratory Research in Clinical and Social Pharmacy February 4, 2026 Shreya Shiju, Rohan Tirumala, Elliot Marseille

Background: As public and scientific interest in psychedelics grows, unsupervised use for health purposes is increasing. In the U.S., past-year hallucinogen use nearly doubled from 2015 to 2023. Many individuals report self-treating physical or psychological symptoms without medical supervision using psychedelics—a practice termed self-medication. Despite this trend, review-level syntheses...

DOI: 10.1016/j.rcsop.2026.100709 (opens in new tab) Full text (opens in new tab) Psilocybin LSD Microdosing Psychedelics +2

Clinical trials

All psilocybin and microdosing trials →